Triptodur Kit Patent Expiration

Triptodur Kit is a drug owned by Azurity Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2019 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 30, 2029. Details of Triptodur Kit's patents and their expiration are given in the table below.


Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10166181 Slow release pharmaceutical composition made of microgranules
Jun, 2029

(4 years from now)

Active


FDA has granted several exclusivities to Triptodur Kit. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Triptodur Kit, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Triptodur Kit.

Exclusivity Information

Triptodur Kit holds 3 exclusivities. All of its exclusivities have expired in 2024. Details of Triptodur Kit's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 29, 2020
Orphan Drug Exclusivity(ODE-149) Jun 29, 2024
Orphan Drug Exclusivity(ODE) Jun 29, 2024

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Triptodur Kit's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Triptodur Kit's generic, the next section provides detailed information on ongoing and past EP oppositions related to Triptodur Kit patents.

Triptodur Kit's oppositions filed in EPO

Triptodur Kit has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 13, 2017, by Generics (Uk) Ltd. This opposition was filed on patent number EP08763237A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP12172232A Apr, 2019 Generics [UK] Ltd Granted and Under Opposition
EP08763237A Sep, 2017 Ferring B.V. Revoked
EP08763237A Sep, 2017 Generics (UK) Ltd Revoked


US patents provide insights into the exclusivity only within the United States, but Triptodur Kit is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Triptodur Kit's family patents as well as insights into ongoing legal events on those patents.

Triptodur Kit's family patents

Triptodur Kit has patent protection in a total of 32 countries. It's US patent count contributes only to 8.2% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Triptodur Kit.

Family Patents

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳



Generic Launch

Generic Release Date:

Triptodur Kit's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 30, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Triptodur Kit Generics:

There are no approved generic versions for Triptodur Kit as of now.





About Triptodur Kit

Triptodur Kit is a drug owned by Azurity Pharmaceuticals Inc. Triptodur Kit uses Triptorelin Pamoate as an active ingredient. Triptodur Kit was launched by Azurity in 2017.

Market Authorisation Date:

Triptodur Kit was approved by FDA for market use on 29 June, 2017.

Active Ingredient:

Triptodur Kit uses Triptorelin Pamoate as the active ingredient. Check out other Drugs and Companies using Triptorelin Pamoate ingredient

Dosage:

Triptodur Kit is available in for suspension, extended release form for intramuscular use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 22.5MG BASE/VIAL FOR SUSPENSION, EXTENDED RELEASE Prescription INTRAMUSCULAR